146 related articles for article (PubMed ID: 28930565)
1. Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells.
Ishiwata T
Front Biosci (Landmark Ed); 2018 Jan; 23(4):626-639. PubMed ID: 28930565
[TBL] [Abstract][Full Text] [Related]
2. Alternative splicing of fibroblast growth factor receptors in human prostate cancer.
Kwabi-Addo B; Ropiquet F; Giri D; Ittmann M
Prostate; 2001 Feb; 46(2):163-72. PubMed ID: 11170144
[TBL] [Abstract][Full Text] [Related]
3. Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases.
Ueda J; Matsuda Y; Yamahatsu K; Uchida E; Naito Z; Korc M; Ishiwata T
Oncogene; 2014 Sep; 33(36):4485-95. PubMed ID: 24077287
[TBL] [Abstract][Full Text] [Related]
4. Addiction of mesenchymal phenotypes on the FGF/FGFR axis in oral squamous cell carcinoma cells.
Osada AH; Endo K; Kimura Y; Sakamoto K; Nakamura R; Sakamoto K; Ueki K; Yoshizawa K; Miyazawa K; Saitoh M
PLoS One; 2019; 14(11):e0217451. PubMed ID: 31682640
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of fibroblast growth factor receptor 2 and its isoforms correlates with a high proliferation rate and poor prognosis in high-grade glioma.
Ohashi R; Matsuda Y; Ishiwata T; Naito Z
Oncol Rep; 2014 Sep; 32(3):1163-9. PubMed ID: 24968791
[TBL] [Abstract][Full Text] [Related]
6. Expression of the FGFR2 mesenchymal splicing variant in epithelial cells drives epithelial-mesenchymal transition.
Ranieri D; Rosato B; Nanni M; Magenta A; Belleudi F; Torrisi MR
Oncotarget; 2016 Feb; 7(5):5440-60. PubMed ID: 26713601
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
Grygielewicz P; Dymek B; Bujak A; Gunerka P; Stanczak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K; Zdzalik D
Gastric Cancer; 2016 Jan; 19(1):53-62. PubMed ID: 25407459
[TBL] [Abstract][Full Text] [Related]
8. Enhanced expression of fibroblast growth factor receptor 2 IIIc promotes human pancreatic cancer cell proliferation.
Ishiwata T; Matsuda Y; Yamamoto T; Uchida E; Korc M; Naito Z
Am J Pathol; 2012 May; 180(5):1928-41. PubMed ID: 22440254
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer.
Matsuda Y; Yoshimura H; Suzuki T; Uchida E; Naito Z; Ishiwata T
Cancer Sci; 2014 Sep; 105(9):1212-9. PubMed ID: 24975163
[TBL] [Abstract][Full Text] [Related]
10. FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression.
Guo M; Liu W; Serra S; Asa SL; Ezzat S
Cancer Res; 2012 Apr; 72(8):2017-27. PubMed ID: 22345151
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor expression reflects cellular differentiation in human oral squamous carcinoma cell lines.
Drugan CS; Paterson IC; Prime SS
Carcinogenesis; 1998 Jun; 19(6):1153-6. PubMed ID: 9667757
[TBL] [Abstract][Full Text] [Related]
12. Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice.
Baraniak AP; Chen JR; Garcia-Blanco MA
Mol Cell Biol; 2006 Feb; 26(4):1209-22. PubMed ID: 16449636
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers.
Wendt MK; Taylor MA; Schiemann BJ; Sossey-Alaoui K; Schiemann WP
Breast Cancer Res; 2014 Mar; 16(2):R24. PubMed ID: 24618085
[TBL] [Abstract][Full Text] [Related]
14. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
15. The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific.
Scotet E; Houssaint E
Biochim Biophys Acta; 1995 Nov; 1264(2):238-42. PubMed ID: 7495869
[TBL] [Abstract][Full Text] [Related]
16. PTBP1 promotes the progression of hepatocellular carcinoma by enhancing the oncogenic splicing switch of FGFR2.
Yu-Ying C; Qian Z; Meng-Hui G; Lan F; Peng-Bo C; Gang-Qiao Z
Yi Chuan; 2024 Jan; 46(1):46-62. PubMed ID: 38230456
[TBL] [Abstract][Full Text] [Related]
17. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing.
Warzecha CC; Sato TK; Nabet B; Hogenesch JB; Carstens RP
Mol Cell; 2009 Mar; 33(5):591-601. PubMed ID: 19285943
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence-based alternative splicing reporters for the study of epithelial plasticity in vivo.
Somarelli JA; Schaeffer D; Bosma R; Bonano VI; Sohn JW; Kemeny G; Ettyreddy A; Garcia-Blanco MA
RNA; 2013 Jan; 19(1):116-27. PubMed ID: 23185039
[TBL] [Abstract][Full Text] [Related]
20. Bleomycin-enhanced alternative splicing of fibroblast growth factor receptor 2 induces epithelial to mesenchymal transition in lung fibrosis.
Chen KJ; Li Q; Weng CM; Duan ZX; Zhang DD; Chen ZQ; Chen J; Wang JM
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30049844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
